Tertiary Lymphoid Structures Gene Signature Predicts Prognosis and Immune Infiltration Analysis in Head and Neck Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

Tertiary Lymphoid Structures Gene Signature Predicts Prognosis and Immune Infiltration Analysis in Head and Neck Squamous Cell Carcinoma

Published:2024-03 Issue:2 Volume:25 Page:88-104
ISSN:1389-2029
Container-title:Current Genomics
language:en
Short-container-title:CG

Author:

Xing Aiyan¹,Lv Dongxiao²³,Wu Changshun⁴⁵,Zhou Kai²³,Zhao Tianhui⁶,Zhao Lihua⁷,Wang Huaqing⁸,Feng Hong²³

Affiliation:

1. Department of Pathology, Shandong University Qilu Hospital, Jinan, Shandong, 250012, China

2. Cancer Center, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China

3. Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China

4. Department of Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China

5. Department of Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China

6. Department of Translational Medicine, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, 214104, China

7. Department of Translational Medicine, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, 214104, China

8. Department of Medical Oncology, Tianjin Union Medical Center, The Affiliated Hospital of Nankai University, Tianjin, 300000, China

Abstract

Objectives: This study aims to assess the prognostic implications of gene signature of the tertiary lymphoid structures (TLSs) in head and neck squamous cell carcinoma (HNSCC) and scrutinize the influence of TLS on immune infiltration. Methods: Patients with HNSCC from the Cancer Genome Atlas were categorized into high/low TLS signature groups based on the predetermined TLS signature threshold. The association of the TLS signature with the immune microenvironment, driver gene mutation status, and tumor mutational load was systematically analyzed. Validation was conducted using independent datasets (GSE41613 and GSE102349). Results: Patients with a high TLS signature score exhibited better prognosis compared to those with a low TLS signature score. The group with a high TLS signature score had significantly higher immune cell subpopulations compared to the group with a low TLS signature score. Moreover, the major immune cell subpopulations and immune circulation characteristics in the tumor immune microenvironment were positively correlated with the TLS signature. Mutational differences in driver genes were observed between the TLS signature high/low groups, primarily in the cell cycle and NRF2 signaling pathways. Patients with TP53 mutations and high TLS signature scores demonstrated a better prognosis compared to those with TP53 wild-type. In the independent cohort, the relationship between TLS signatures and patient prognosis and immune infiltration was also confirmed. Additionally, immune-related biological processes and signaling pathways were activated with elevated TLS signature. Conclusion: High TLS signature is a promising independent prognostic factor for HNSCC patients. Immunological analysis indicated a correlation between TLS and immune cell infiltration in HNSCC. These findings provide a theoretical basis for future applications of TLS signature in HNSCC prognosis and immunotherapy.

Publisher

Bentham Science Publishers Ltd.

Reference51 articles.

1. Mandal R.; Şenbabaoğlu Y.; Desrichard A.; Havel J.J.; Dalin M.G.; Riaz N.; Lee K.W.; Ganly I.; Hakimi A.A.; Chan T.A.; Morris L.G.T.; The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016,1(17),e89829

2. Chi A.C.; Day T.A.; Neville B.W.; Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin 2015,65(5),401-421

3. Johnson D.E.; Burtness B.; Leemans C.R.; Lui V.W.Y.; Bauman J.E.; Grandis J.R.; Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020,6(1),92

4. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249

5. Burtness B.; Harrington K.J.; Greil R.; Soulières D.; Tahara M.; de Castro G.; Psyrri A.; Basté N.; Neupane P.; Bratland Å.; Fuereder T.; Hughes B.G.M.; Mesía R.; Ngamphaiboon N.; Rordorf T.; Wan Ishak W.Z.; Hong R.L.; González Mendoza R.; Roy A.; Zhang Y.; Gumuscu B.; Cheng J.D.; Jin F.; Rischin D.; Lerzo G.; Tatangelo M.; Varela M.; Zarba J.J.; Boyer M.; Gan H.; Gao B.; Hughes B.; Mallesara G.; Rischin D.; Taylor A.; Burian M.; Fuereder T.; Greil R.; Barrios C.H.; de Castro Junior D.O.; Castro G.; Franke F.A.; Girotto G.; Lima I.P.F.; Nicolau U.R.; Pinto G.D.J.; Santos L.; Victorino A-P.; Chua N.; Couture F.; Gregg R.; Hansen A.; Hilton J.; McCarthy J.; Soulieres D.; Ascui R.; Gonzalez P.; Villanueva L.; Torregroza M.; Zambrano A.; Holeckova P.; Kral Z.; Melichar B.; Prausova J.; Vosmik M.; Andersen M.; Gyldenkerne N.; Jurgens H.; Putnik K.; Reinikainen P.; Gruenwald V.; Laban S.; Aravantinos G.; Boukovinas I.; Georgoulias V.; Psyrri A.; Kwong D.; Al-Farhat Y.; Csoszi T.; Erfan J.; Horvai G.; Landherr L.; Remenar E.; Ruzsa A.; Szota J.; Billan S.; Gluck I.; Gutfeld O.; Popovtzer A.; Benasso M.; Bui S.; Ferrari V.; Licitra L.; Nole F.; Fujii T.; Fujimoto Y.; Hanai N.; Hara H.; Matsumoto K.; Mitsugi K.; Monden N.; Nakayama M.; Okami K.; Oridate N.; Shiga K.; Shimizu Y.; Sugasawa M.; Tahara M.; Takahashi M.; Takahashi S.; Tanaka K.; Ueda T.; Yamaguchi H.; Yamazaki T.; Yasumatsu R.; Yokota T.; Yoshizaki T.; Kudaba I.; Stara Z.; Wan Ishak W.Z.; Cheah S.K.; Aguilar Ponce J.; Gonzalez Mendoza R.; Hernandez Hernandez C.; Medina Soto F.; Buter J.; Hoeben A.; Oosting S.; Suijkerbuijk K.; Bratland A.; Brydoey M.; Alvarez R.; Mas L.; Caguioa P.; Querol J.; Regala E.E.; Tamayo M.B.; Villegas E.M.; Kawecki A.; Karpenko A.; Klochikhin A.; Smolin A.; Zarubenkov O.; Goh B.C.; Cohen G.; du Toit J.; Jordaan C.; Landers G.; Ruff P.; Szpak W.; Tabane N.; Brana I.; Iglesias Docampo L.; Lavernia J.; Mesia R.; Abel E.; Muratidu V.; Nielsen N.; Cristina V.; Rordorf T.; Rothschild S.; Hong R-L.; Wang H-M.; Yang M-H.; Yeh S-P.; Yen C-J.; Ngamphaiboon N.; Soparattanapaisarn N.; Sriuranpong V.; Aksoy S.; Cicin I.; Ekenel M.; Harputluoglu H.; Ozyilkan O.; Harrington K.; Agarwala S.; Ali H.; Alter R.; Anderson D.; Bruce J.; Burtness B.; Campbell N.; Conde M.; Deeken J.; Edenfield W.; Feldman L.; Gaughan E.; Goueli B.; Halmos B.; Hegde U.; Hunis B.; Jotte R.; Karnad A.; Khan S.; Laudi N.; Laux D.; Martincic D.; McCune S.; McGaughey D.; Misiukiewicz K.; Mulford D.; Nadler E.; Neupane P.; Nunnink J.; Ohr J.; O’Malley M.; Patson B.; Paul D.; Popa E.; Powell S.; Redman R.; Rella V.; Rocha Lima C.; Sivapiragasam A.; Su Y.; Sukari A.; Wong S.; Yilmaz E.; Yorio J.; Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019,394(10212),1915-1928